Bionano Announces Two-Fold Increase in OGM Studies Presented at the 2026 American College of Medical Genetics and Genomics (ACMG) Annual Clinical Genetics Meeting

Rhea-AI Summary

Bionano (NASDAQ: BNGO) reported that 12 optical genome mapping (OGM) studies were presented at the 2026 ACMG Annual Meeting (March 14–18), a two-fold increase versus 2025. Presentations included four oral talks and eight posters across cancer genomics and constitutional genetic disorders.

The presentations highlighted OGM's ability to detect structural variants missed by other methods; a Greenwood Genetic Center workshop and a Baylor Genetics commercial OGM service release were also noted.

News Market Reaction – BNGO

+1.80%

1 alert

+1.80% News Effect

On the day this news was published, BNGO gained 1.80%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

ACMG studies: 12 studies Oral presentations: 4 oral presentations Poster presentations: 8 poster presentations +1 more

4 metrics

ACMG studies 12 studies Presented at 2026 ACMG Annual Clinical Genetics Meeting

Oral presentations 4 oral presentations Part of 12 OGM-related ACMG studies

Poster presentations 8 poster presentations Part of 12 OGM-related ACMG studies

Adoption increase two-fold increase Increase in OGM-related studies vs 2025 ACMG meeting

Market Reality Check

Price: $1.12 Vol: Volume 87,676 is at a 0.8...

normal vol

$1.12 Last Close

Volume Volume 87,676 is at a 0.86 relative level vs 20-day average. normal

Technical Shares at $1.11 are trading below the $2.28 200-day moving average and near the 52-week low.

Peers on Argus

Momentum scanner shows only one peer (LUCY) moving, down ~5.36%, while BNGO show...

1 Down

Momentum scanner shows only one peer (LUCY) moving, down ~5.36%, while BNGO shows no marked move. Broader peers in Medical Instruments & Supplies are mixed, suggesting this ACMG-related OGM update is stock-specific rather than part of a sector rotation.

Historical Context

5 past events · Latest: Mar 09 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Mar 09	Earnings call scheduling	Positive	+0.9%	Announced date and webcast details for Q4 and full-year 2025 results.
Feb 27	Symposium wrap-up	Positive	+0.0%	Summarized Symposium 2026 with 35 speakers and 50 posters on OGM.
Feb 26	Symposium Day 3	Positive	+0.0%	Highlighted OGM use in constitutional genetic disorders with strong attendance.
Feb 25	Symposium Day 2	Positive	+2.7%	Showcased OGM in oncology and cell & gene therapy applications.
Feb 24	Symposium Day 1	Positive	-0.9%	Reported OGM’s concordance with cytogenetics in hematologic malignancies.

Pattern Detected

Recent upbeat event and symposium news often saw muted or mixed price reactions, with several positive OGM updates not translating into consistent upside.

Recent Company History

Over the last month, Bionano highlighted multiple events showcasing optical genome mapping (OGM), including Symposium 2026 (Days 1–4) and an upcoming March 23, 2026 earnings call. These updates emphasized growing adoption, complex structural variant detection, and broad international participation. Despite this, price reactions were small or mixed. The latest ACMG meeting news continues the theme of expanding OGM use in cancer and constitutional genetics without clear evidence of strong pre-news momentum.

Market Pulse Summary

This announcement underscores growing adoption of optical genome mapping (OGM), with 12 ACMG present...

Analysis

This announcement underscores growing adoption of optical genome mapping (OGM), with 12 ACMG presentations and a two-fold increase over 2025. It reinforces earlier Symposium 2026 updates that emphasized OGM’s role in cancer and constitutional genetics. Historically, similar event-driven news produced modest or mixed price reactions. Investors may watch upcoming milestones like the March 23, 2026 earnings call and further clinical or commercial updates to gauge whether rising scientific use translates into financial traction.

Key Terms

optical genome mapping, structural variants, hematologic malignancies, cytogenetics, +2 more

6 terms

optical genome mapping medical

"The studies illustrated how optical genome mapping (OGM) can drive discoveries..."

Optical genome mapping is a laboratory technique that produces a high-resolution picture of a person’s long DNA strands to find large structural changes such as missing, extra, or rearranged pieces. For investors, it matters because the method can improve diagnosis, speed development of genetic tests and therapies, and influence regulatory approvals and market demand for companies offering more accurate or faster genomic tools — think of it as a wide-angle camera that reveals large-scale defects traditional microscopes might miss.

structural variants medical

"...by detecting structural variants (SVs) that may be missed by other techniques..."

Structural variants are large-scale changes in an organism’s DNA—such as missing, extra, flipped, or rearranged chunks of genetic material—that are like tearing out, duplicating, or reshuffling chapters in a book. Investors should care because these changes can drive or explain diseases, alter how well diagnostics and therapies work, and shift the commercial and regulatory outlook for drugs, tests, and gene-based treatments.

hematologic malignancies medical

"...across cancer genomics, such as hematologic malignancies, and constitutional..."

Hematologic malignancies are types of cancers that start in the blood or the organs responsible for blood production, like the bone marrow and lymph nodes. They matter because they can disrupt normal blood functions, leading to issues like weakness, infections, or abnormal growths, and often require specialized treatments.

cytogenetics medical

"...why the technique is becoming central to modern cytogenetics and complementing..."

Cytogenetics is the study of chromosomes—the structures inside cells that hold genes—and how their number or shape can change. For investors in healthcare and biotech, cytogenetics matters because those chromosomal changes can diagnose diseases, determine which patients will benefit from a therapy, and influence regulatory approval and market size; think of it as a blueprint check that reveals whether a treatment targets the right problem.

short-read sequencing medical

"...complementing molecular genome analysis methods such as short-read and long-read sequencing..."

A laboratory method that reads DNA or RNA in many short fragments and stitches those pieces together like a jigsaw puzzle to determine the full genetic sequence. For investors, it matters because this approach is typically faster and cheaper than alternatives, shaping product costs, throughput and clinical utility; its strengths and limits (for example, missing large-scale rearrangements) affect revenue potential, competitive advantage and technical risk for life‑science companies.

long-read sequencing medical

"...complementing molecular genome analysis methods such as short-read and long-read sequencing..."

Long-read sequencing is a laboratory method that reads much longer stretches of DNA at once than older approaches, giving a clearer, more continuous picture of a genome—like reading whole sentences instead of just chopped-up words. For investors, it matters because it can improve accuracy of genetic tests, speed up drug research, reduce costly follow-up testing, and create competitive advantages for companies that develop or use the technology in diagnostics and therapeutics.

AI-generated analysis. Not financial advice.

SAN DIEGO, March 17, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics (NASDAQ: BNGO) participated in the 2026 American College of Medical Genetics and Genomics Annual Meeting (ACMG), held March 14–18 in Baltimore, Maryland. Twelve studies, representing a two-fold increase over the number of studies in 2025, were presented as either oral (4) or poster presentations (8). The studies illustrated how optical genome mapping (OGM) can drive discoveries in genomics by detecting structural variants (SVs) that may be missed by other techniques across cancer genomics, such as hematologic malignancies, and constitutional genetic disorders, including rare diseases and reproductive disorders. Additionally, the Greenwood Genetic Center (GGC) hosted a workshop led by Nikhil Sahajpal, PhD, FACMG entitled Ask the OGM Expert, in which attendees could seek advice about the application of OGM or use of OGM services from GGC, and Baylor Genetics, a national reference laboratory located in Texas, announced the commercial release of a service that makes OGM data available to the research community.

Scientific Presentations and Posters:

Oral Presentations as part of Scientific Sessions:

• Yassmine Akkari, Nationwide Children's Hospital: Optical Genome Mapping in Cancer: Bridging Cytogenetics and Molecular Genomics
  
• Paige Van Haute, University of Texas MD Anderson Cancer Center: Improving Detection of Variant MECOM Rearrangements Through Optical Genome Mapping and Repurposed Targeted RNA-Seq
  
• Sichen Liang, Johns Hopkins University: Optical Genome Mapping for Cytogenetic Analysis in Multiple Myeloma: Real-world Evidence
  
• Nikhil S. Sahajpal, Greenwood Genetic Center: Increased Success Rate with Optical Genome Mapping in Pediatric Rare Disease Setting: 1-year Experience at the Greenwood Genetic Center
  

Posters:

• Xinrui Shi, Cincinnati Children's Hospital Medical Center: Implementation of Optical Genome Mapping at Cincinnati Children's Hospital Medical Center (P649)
  
• Xiaolan Fang, Henry Ford Health and Michigan State University: Optical Genome Mapping for Hematologic Malignancy-Henry Ford Health System Experience (P675)
  
• Atlas Mashayekhi Sardoo, Greenwood Genetic Center: When Routine Testing Is Normal: Optical Genome Mapping Identifies a Hidden Rearrangement in Multigenerational Case affected with Split-Hand/Foot Malformation (P695)
  
• Mona Aminbeidokhti, University of California San Francisco: Integrative Exome, Optical Genome Mapping, and Variant-Effect Modeling in Consanguineous Couples with Recurrent Pregnancy Loss (P753)
  
• Jessica A. Cooley Coleman, Greenwood Genetic Center: Optical Genome Mapping Resolves Positional Context of DMD Structural Variants for Accurate Results (P580)
  
• Gordana Raca, Children's Hospital Los Angeles and University of Southern California: Decoding Chromoanagenesis in Cases of Undiagnosed Congenital Disorders by Optical Genome Mapping (P638)
  
• Claire McCarthy, Henry Ford Health System: Characterization of an Atypical PML::RARA Rearrangement: Utility of Optical Genome Mapping and Implications for Hematological Malignancies (P690)
  
• Mehmet Akif Yücesoy, Istanbul University and Detagen Genetic Diseases Diagnosis and Evaluation Center: Optical Genome Mapping Reveals Complex 22q13 Rearrangements in SHANK3-Unrelated Phelan-McDermid Syndrome (P707)
  

The scientific program for the event is available at the ACMG website linked here https://eppro02.ativ.me/web/planner.php?id=ACMG26LITE

“We are pleased to see the increasing application of OGM. The studies presented at the 2026 ACMG Annual Meeting demonstrate the potential of OGM to help researchers worldwide better investigate complex genomic variation. Clinical researchers are continually expanding what’s possible with OGM, and their real‑world results illustrate why the technique is becoming central to modern cytogenetics and complementing molecular genome analysis methods such as short-read and long-read sequencing,” commented Erik Holmlin, PhD, president and chief executive officer of Bionano.

For more information on Bionano’s OGM solutions, visit www.bionano.com.

About Bionano

Bionano is a provider of genome analysis solutions that can enable researchers and clinicians to reveal answers to challenging questions in biology and medicine. The Company’s mission is to transform the way the world sees the genome through optical genome mapping (OGM) solutions, diagnostic services and software. The Company offers OGM solutions for applications across basic, translational and clinical research. The Company also offers an industry-leading, platform-agnostic genome analysis software solution, and nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology. Through its Lineagen, Inc. d/b/a Bionano Laboratories business, the Company also offers OGM-based diagnostic testing services.

For more information, visit www.bionano.com or www.bionanolaboratories.com.

Bionano’s products are for research use only and not for use in diagnostic procedures.

Forward-Looking Statements of Bionano Genomics

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “becoming,” “can,” “may,” “potential,” and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements describe future expectations, plans, results, or strategies, among other things, and in this release include, but are not limited to statements about: the ability of OGM to detect SVs missed by other cytogenetic and sequencing techniques; the ability and utility of OGM to help researchers investigate complex genomic variations; the ability and utility of OGM to become central to modern cytogenetics and complementing molecular genome analysis methods such as short-read and long-read sequencing; other statements not of historical fact presented in the posters and presentations at the 2026 ACMG Annual Meeting. Each of these forward-looking statements involves risks and uncertainties. Accordingly, investors and prospective investors are cautioned not to place undue reliance on these forward-looking statements as they involve inherent risk and uncertainty (both general and specific) and should note that they are provided as a general guide only and should not be relied on as an indication or guarantee of future performance. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: the failure of OGM to detect SVs missed other cytogenetic and sequencing techniques; the failure of OGM to help researchers investigate complex genomic variations; the failure of OGM to become central to modern cytogenetics and complementing molecular genome analysis methods such as short-read and long-read sequencing; future publications, posters, or presentations that contradict or differ from the posters and presentations referenced in this press release; the failure of OGM be useful in the applications described in the presentation and posters referenced in this press release; our ability to continue as a “going concern”, which requires us to manage costs and obtain significant additional financing to fund our strategic plans and commercialization efforts; our ability to execute on our strategy and achieve our objectives; our ability to further deploy new products and applications for our technology platforms; our expectations and beliefs regarding future growth of the business and the markets in which we operate; our ability to consummate any strategic alternatives including the risk that if we fail to obtain additional financing we may seek relief under applicable insolvency laws; the size and growth potential of the markets for our products, and our ability to serve those markets; the rate and degree of market acceptance of our products; our ability to manage the growth of our business and integrate acquired businesses; our ability to expand our commercial organization to address effectively existing and new markets that we intend to target; the impact from future regulatory, judicial, and legislative changes or developments in the U.S. and foreign countries; our ability to compete effectively in a competitive industry; the introduction of competitive technologies or improvements in existing technologies and the success of any such technologies; the performance of our third-party contract sales organizations, suppliers and manufacturers; our ability to attract and retain key scientific or management personnel; the accuracy of our estimates regarding expenses, future revenues, reimbursement rates, capital requirements and needs for additional financing; the impact of adverse geopolitical and macroeconomic developments, such as recent and future bank failures, ongoing international conflicts, and related sanctions, regional or global pandemics, inflation, tariffs, increased cost of goods, supply chain issues, and global financial market conditions on our business and operations, as well as the business or operations of our suppliers, customers, manufacturers, research partners and other third parties with whom we conduct business and our expectations with respect to the duration of such impacts and the resulting effects on our business; our ability to realize the anticipated benefits and synergies of our prior and any future acquisitions or other strategic transactions; our ability to attract collaborators and strategic partnerships; and the risks and uncertainties associated with our business and financial condition in general, including the risks and uncertainties described in our filings with the Securities and Exchange Commission (“SEC”), including, without limitation, our Annual Report on Form 10-K for the year ended December 31, 2024, any subsequently filed Quarterly Reports on Form 10-Q and in other filings subsequently made by us with the SEC. All forward-looking statements contained in this press release speak only as of the date on which they were made and are based on management’s assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise, except as may be required by law.

CONTACTS
Company Contact:
Erik Holmlin, CEO
Bionano Genomics, Inc.
+1 (858) 888-7610
eholmlin@bionano.com

Investor Relations:
Webb Campbell
Gilmartin Group
+1 (858) 888-7625

FAQ

How many OGM studies did Bionano (BNGO) have at the 2026 ACMG meeting?

Bionano had 12 OGM studies presented at ACMG 2026, doubling the count from 2025. According to the company, those included 4 oral and 8 poster presentations across cancer and constitutional genetics.

What dates did Bionano's presentations occur at the ACMG 2026 meeting (BNGO)?

Presentations took place during the ACMG Annual Meeting, held March 14–18, 2026 in Baltimore. According to the company, the schedule included oral and poster sessions and a Greenwood Genetic Center workshop.

Which clinical areas did Bionano's OGM studies (BNGO) cover at ACMG 2026?

The OGM studies covered cancer genomics (including hematologic malignancies) and constitutional genetic disorders such as rare and reproductive disorders. According to the company, sessions showed OGM detecting structural variants other methods may miss.

Did Bionano (BNGO) report any workshops or service launches related to OGM at ACMG 2026?

Yes. Greenwood Genetic Center hosted an Ask the OGM Expert workshop, and Baylor Genetics announced a commercial service to share OGM data. According to the company, both aim to expand OGM access and practitioner support.

What types of presentations did Bionano (BNGO) list from ACMG 2026?

Bionano listed 4 oral presentations8 poster presentations

How does Bionano (BNGO) describe OGM's role based on ACMG 2026 presentations?

Bionano describes OGM as complementary to short- and long-read sequencing